AU548268B2 - 2-ammo-5-hydroxy-4-methylpyrimidinme derivatives - Google Patents

2-ammo-5-hydroxy-4-methylpyrimidinme derivatives

Info

Publication number
AU548268B2
AU548268B2 AU33768/84A AU3376884A AU548268B2 AU 548268 B2 AU548268 B2 AU 548268B2 AU 33768/84 A AU33768/84 A AU 33768/84A AU 3376884 A AU3376884 A AU 3376884A AU 548268 B2 AU548268 B2 AU 548268B2
Authority
AU
Australia
Prior art keywords
hydroxy
compounds
derivatives
amino
methylpyrimidinme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU33768/84A
Other languages
English (en)
Other versions
AU3376884A (en
Inventor
John Lawrence Lamattina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of AU3376884A publication Critical patent/AU3376884A/en
Application granted granted Critical
Publication of AU548268B2 publication Critical patent/AU548268B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48Nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Hydrogenated Pyridines (AREA)
AU33768/84A 1983-10-03 1984-10-02 2-ammo-5-hydroxy-4-methylpyrimidinme derivatives Ceased AU548268B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/538,233 US4554276A (en) 1983-10-03 1983-10-03 2-Amino-5-hydroxy-4-methylpyrimidine derivatives
US538233 1983-10-03

Publications (2)

Publication Number Publication Date
AU3376884A AU3376884A (en) 1985-04-18
AU548268B2 true AU548268B2 (en) 1985-12-05

Family

ID=24146051

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33768/84A Ceased AU548268B2 (en) 1983-10-03 1984-10-02 2-ammo-5-hydroxy-4-methylpyrimidinme derivatives

Country Status (25)

Country Link
US (1) US4554276A (US07094801-20060822-C00212.png)
EP (1) EP0138464B1 (US07094801-20060822-C00212.png)
JP (1) JPS6094970A (US07094801-20060822-C00212.png)
KR (1) KR860001818B1 (US07094801-20060822-C00212.png)
AT (1) ATE47999T1 (US07094801-20060822-C00212.png)
AU (1) AU548268B2 (US07094801-20060822-C00212.png)
CA (1) CA1215985A (US07094801-20060822-C00212.png)
DD (1) DD232698A5 (US07094801-20060822-C00212.png)
DE (1) DE3480474D1 (US07094801-20060822-C00212.png)
DK (1) DK162222C (US07094801-20060822-C00212.png)
EG (1) EG16355A (US07094801-20060822-C00212.png)
ES (1) ES536499A0 (US07094801-20060822-C00212.png)
FI (1) FI84479C (US07094801-20060822-C00212.png)
GR (1) GR80512B (US07094801-20060822-C00212.png)
HU (1) HU194186B (US07094801-20060822-C00212.png)
IE (1) IE57633B1 (US07094801-20060822-C00212.png)
IL (1) IL73104A (US07094801-20060822-C00212.png)
NO (1) NO170883C (US07094801-20060822-C00212.png)
NZ (1) NZ209740A (US07094801-20060822-C00212.png)
PH (1) PH21038A (US07094801-20060822-C00212.png)
PL (1) PL148590B1 (US07094801-20060822-C00212.png)
PT (1) PT79278B (US07094801-20060822-C00212.png)
SU (1) SU1342417A3 (US07094801-20060822-C00212.png)
YU (1) YU44058B (US07094801-20060822-C00212.png)
ZA (1) ZA847731B (US07094801-20060822-C00212.png)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711888A (en) 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines
IE58373B1 (en) * 1986-06-18 1993-09-08 Bloomfield Frederick Jacob 5-Lipoxygenase pathway inhibitors
WO1989000423A1 (en) * 1987-07-09 1989-01-26 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
HU206203B (en) * 1987-12-02 1992-09-28 Pfizer Process for producing acyl derivatives of hydroxypyrimidines
US4910204A (en) * 1988-06-28 1990-03-20 Pfizer Inc. 2-amino-5-hydroxy-4-pyrimidones
US5071852A (en) * 1988-12-14 1991-12-10 Pfizer Inc. Derivatives of 5-hydroxy and 5-methoxy 2-amino-pyrimidines as inhibitors of interleukin-1 production
IL92586A (en) * 1988-12-14 1994-06-24 Pfizer History of 5-hydroxy and 5-methoxy-2-aminopyrimidines as inhibitors of interleukin-1 formation
US4940712A (en) * 1989-05-26 1990-07-10 Pfizer Inc. Derivatives of hydroxyprimidines as leukotriene synthesis inhibitors
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5177079A (en) * 1991-01-31 1993-01-05 Warner-Lambert Company 2-substituted-4,6-di-tertiarybutyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5248682A (en) * 1991-01-31 1993-09-28 Warner-Lambert Company 2-substituted-4,6-di-tertiary-butyl-5-hydroxy-1,3-pyrimidines useful as antiinflammatory agents
US5220025A (en) * 1992-02-24 1993-06-15 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
WO1994001403A1 (en) * 1992-07-08 1994-01-20 Shell Internationale Research Maatschappij B.V. Piperidine derivatives
EP0750496A1 (en) * 1994-03-14 1997-01-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
WO2002000683A2 (en) * 2000-06-23 2002-01-03 Vanderbilt University Novel chain-breaking antioxidants
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
EP2260837A1 (en) * 2001-06-01 2010-12-15 Pozen, Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
DE102004054080A1 (de) * 2004-11-09 2006-05-11 Wella Ag Haut- oder Haarbehandlungsmittel mit Schutzeffekt
AP2007004047A0 (en) 2005-01-20 2007-06-30 Pfizer Ltd Substituted triazole derivatives as oxtocin antagonists
US8367669B2 (en) * 2005-06-15 2013-02-05 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
US9133212B1 (en) 2005-06-15 2015-09-15 Vanderbilt University Inhibitors of hemeprotein-catalyzed lipid peroxidation
PL2240018T3 (pl) 2008-01-04 2017-01-31 Schabar Res Ass Llc Kompozycja zawierająca środek przeciwbólowy i przeciwhistaminowy
EA201100313A1 (ru) 2008-09-09 2011-10-31 Астразенека Аб Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CA2764963C (en) 2009-06-25 2016-11-01 Astrazeneca Ab Method for treating a patient at risk for developing an nsaid-associated ulcer
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
EP4181912A1 (en) 2020-07-15 2023-05-24 Schabar Research Associates LLC Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000138A (en) * 1966-03-31 1976-12-28 Imperial Chemical Industries Limited Organic compounds and compositions containing them
US3932617A (en) * 1974-05-24 1976-01-13 The Upjohn Company Interferon induction
DE2814984A1 (de) * 1978-04-07 1979-10-18 Bayer Ag Pyrimidin(5)yl-(thiono)(thiol)- phosphor(phosphon)-saeureester bzw. -esteramide, verfahren zu ihrer herstellung und ihre verwendung als insektizide und akarizide
IN153791B (US07094801-20060822-C00212.png) * 1979-03-10 1984-08-18 Soc D Etudes Prod Chimique
US4416885A (en) * 1979-11-02 1983-11-22 Huve Pierre M Use of isopropylaminopyrimidine in the chemotherapy of muscular dystrophy, myopathy and myotonia
OA07362A (fr) * 1980-10-27 1984-06-30 May & Baker Ltd Dérivés de la pyrimidine, leur procédé de préparation et les compositions les contenant.
US4435396A (en) * 1982-05-10 1984-03-06 Pfizer Inc. Antiulcer 2-guanidino-4-(2-substituted-amino-4-imidazolyl)thiazoles and process therefor

Also Published As

Publication number Publication date
DK472184A (da) 1985-04-04
JPS6094970A (ja) 1985-05-28
FI843864A0 (fi) 1984-10-02
US4554276A (en) 1985-11-19
NO843968L (no) 1985-04-09
IL73104A (en) 1987-12-20
SU1342417A3 (ru) 1987-09-30
FI84479C (fi) 1991-12-10
PL148590B1 (en) 1989-11-30
PH21038A (en) 1987-07-03
HUT35651A (en) 1985-07-29
KR860001818B1 (ko) 1986-10-24
DK472184D0 (da) 1984-10-02
KR850003402A (ko) 1985-06-17
GR80512B (en) 1985-02-01
ATE47999T1 (de) 1989-12-15
IE57633B1 (en) 1993-02-10
PT79278A (en) 1984-10-01
EP0138464B1 (en) 1989-11-15
IL73104A0 (en) 1984-12-31
NO170883C (no) 1992-12-23
DE3480474D1 (de) 1989-12-21
JPH0528707B2 (US07094801-20060822-C00212.png) 1993-04-27
DD232698A5 (de) 1986-02-05
PT79278B (en) 1986-11-18
YU169584A (en) 1987-02-28
HU194186B (en) 1988-01-28
YU44058B (en) 1990-02-28
CA1215985A (en) 1986-12-30
ES8601924A1 (es) 1985-11-16
ZA847731B (en) 1986-05-28
FI843864L (fi) 1985-04-04
ES536499A0 (es) 1985-11-16
IE842494L (en) 1985-04-03
EP0138464A2 (en) 1985-04-24
EG16355A (en) 1987-04-30
FI84479B (fi) 1991-08-30
NZ209740A (en) 1987-04-30
NO170883B (no) 1992-09-14
DK162222B (da) 1991-09-30
AU3376884A (en) 1985-04-18
DK162222C (da) 1992-03-02
EP0138464A3 (en) 1986-08-20
PL249833A1 (en) 1985-06-04

Similar Documents

Publication Publication Date Title
AU548268B2 (en) 2-ammo-5-hydroxy-4-methylpyrimidinme derivatives
NZ208529A (en) 2-pyrimidinyl-1-piperazine derivatives and pharmaceutical compositions
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
NO930693L (no) Mometasonfuroatmonohydrat, fremgangsmaate for fremstillingav dette og farmasoeytiske preprater
ES8404332A1 (es) Procedimiento para preparar acidos omega-(1,4,5-trifenilimidazol-2-iloxi)-alcanicos
ES485068A1 (es) Un procedimiento para preparar derivados de piridina o piri-midina
ES8504977A1 (es) Procedimiento para preparar -monohidrato de (+)-catequina.
AU586808B2 (en) Purine derivatives
SE8405588D0 (sv) New compounds
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
ES8300747A1 (es) Procedimiento para la preparacion de derivados de acido in- dolacetico
ES8606375A1 (es) Un procedimiento para preparar un derivado de aminoprpilaminobleomicina
RU94035756A (ru) Производные имидазола, являющиеся ингибиторами питокинов, способы их получения, фармацевтическая композиция
JPS5265261A (en) Synthesis of 1alpha-hyaroxy-provitamine d compounds